RT Journal Article
SR Electronic
T1 Association of hypertension with mortality in patients hospitalised with COVID-19
JF Open Heart
JO Open Heart
FD British Cardiovascular Society
SP e001853
DO 10.1136/openhrt-2021-001853
VO 8
IS 2
A1 Kunwardeep S Bhatia
A1 Hari P Sritharan
A1 Jonathan Ciofani
A1 Justin Chia
A1 Usaid K Allahwala
A1 Karina Chui
A1 Daniel Nour
A1 Sheran Vasanthakumar
A1 Dhanvee Khandadai
A1 Pavithra Jayadeva
A1 Rohan Bhagwandeen
A1 David Brieger
A1 Christopher Choong
A1 Anthony Delaney
A1 Girish Dwivedi
A1 Benjamin Harris
A1 Graham Hillis
A1 Bernard Hudson
A1 George Javorski
A1 Nigel Jepson
A1 Logan Kanagaratnam
A1 George Kotsiou
A1 Astin Lee
A1 Sidney T Lo
A1 Andrew I MacIsaac
A1 Brendan McQuillan
A1 Isuru Ranasinghe
A1 Antony Walton
A1 James Weaver
A1 William Wilson
A1 Andy S C Yong
A1 John Zhu
A1 William Van Gaal
A1 Leonard Kritharides
A1 Clara K Chow
A1 Ravinay Bhindi
YR 2021
UL http://openheart.bmj.com/content/8/2/e001853.abstract
AB Objective To assess whether hypertension is an independent risk factor for mortality among patients hospitalised with COVID-19, and to evaluate the impact of ACE inhibitor and angiotensin receptor blocker (ARB) use on mortality in patients with a background of hypertension.Method This observational cohort study included all index hospitalisations with laboratory-proven COVID-19 aged ≥18 years across 21 Australian hospitals. Patients with suspected, but not laboratory-proven COVID-19, were excluded. Registry data were analysed for in-hospital mortality in patients with comorbidities including hypertension, and baseline treatment with ACE inhibitors or ARBs.Results 546 consecutive patients (62.9±19.8 years old, 51.8% male) hospitalised with COVID-19 were enrolled. In the multivariable model, significant predictors of mortality were age (adjusted OR (aOR) 1.09, 95% CI 1.07 to 1.12, p<0.001), heart failure or cardiomyopathy (aOR 2.71, 95% CI 1.13 to 6.53, p=0.026), chronic kidney disease (aOR 2.33, 95% CI 1.02 to 5.32, p=0.044) and chronic obstructive pulmonary disease (aOR 2.27, 95% CI 1.06 to 4.85, p=0.035). Hypertension was the most prevalent comorbidity (49.5%) but was not independently associated with increased mortality (aOR 0.92, 95% CI 0.48 to 1.77, p=0.81). Among patients with hypertension, ACE inhibitor (aOR 1.37, 95% CI 0.61 to 3.08, p=0.61) and ARB (aOR 0.64, 95% CI 0.27 to 1.49, p=0.30) use was not associated with mortality.Conclusions In patients hospitalised with COVID-19, pre-existing hypertension was the most prevalent comorbidity but was not independently associated with mortality. Similarly, the baseline use of ACE inhibitors or ARBs had no independent association with in-hospital mortality.Data are available upon reasonable request.